Lirum Therapeutics, Inc. (LRTX)

Lirum Therapeutics will go public soon, but the exact IPO date is still unknown.
IPO Price Range
$10.00 - $12.00
Shares Offered
Deal Size
Chart not available yet
Data will show when the stock starts trading.
Market Cap 101.97M
Revenue (ttm) n/a
Net Income (ttm) 2.20M
Shares Out 9.27M
EPS (ttm) 0.24
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open n/a
Previous Close n/a
Day's Range n/a
52-Week Range n/a
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About LRTX

Lirum Therapeutics is an innovative, clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases through the acquisition, development, and commercialization of novel drug candidates with compelling mechanisms of action, regulatory pathways, and commercial opportunities. Our lead product candidate, LX-101, is a novel, clinical stage, next generation, precision-engineered targeted therapy directed to the IGF-1R. The IGF-1/IGF-1R pathway has been implicated in a host of diseases. LX-101 has been clinically evaluated ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2021
Employees 3
Stock Exchange NASDAQ
Ticker Symbol LRTX
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements


Oncology and autoimmune biotech Lirum Therapeutics files for a $25 million IPO

Lirum Therapeutics, a Phase 1 biotech developing an in-licensed therapy for cancer and autoimmune diseases, filed on Monday with the SEC to raise up to $25 million in an initial public offering.

2 months ago - Renaissance Capital

Lirum Therapeutics IPO Registration Document (S-1)

Lirum Therapeutics has filed to go public with an IPO on the NASDAQ.

2 months ago - SEC